REGISTER
First iPSC Therapies Approved: Is Parkinson’s Care Entering a New Era?
Japan has conditionally approved the first induced-pluripotent-stem-cell therapies in the world, igniting hope and debate over the future of regenerative medicine.

Japan has conditionally approved two induced-pluripotent-stem-cell therapies, Amchepry for Parkinson's disease and ReHeart for ischemic cardiomyopathy, making them the first iPSC regenerative-medicine products in the world to receive such approval.

First in the world: approval now, more evidence later

Amchepry was developed from dopaminergic precursor cells derived from iPSCs and implanted into the brain, while ReHeart is an iPSC-derived myocardial patch placed on the surface of the heart. Early clinical studies reported promising results in very small numbers of patients.

The announcement has been welcomed as a milestone by some specialists, but others have called it a regulatory gamble because the evidence comes from trials involving only single-digit numbers of patients and lacking large controlled comparisons.

Under Japanese policy, the products must now undergo seven years of post-marketing surveillance and evaluation before they can seek full approval.

Can this launch a new era of regenerative medicine?

Prof. Jiong Shi told MedJ that the approvals are a landmark in stem-cell therapy and that he remains optimistic. At the same time, he noted that tumorigenicity, short follow-up, and small sample sizes remain major concerns, and that most countries, including China, still generally require a conventional phase III path.

He also pointed out that more flexible regulation can accelerate access for patients with severe diseases who have few other options, so long as post-marketing oversight remains strict.

China has also made rapid progress in pluripotent-stem-cell research. In 2025, Prof. Shi's team reported functional cure in a patient with advanced early-onset Parkinson's disease using an iPSC-based therapy. Beyond Parkinson's disease, iPSCs are being explored in retinal disease, diabetes, spinal-cord injury, and other serious conditions.

Whether the Japanese approvals will truly mark the beginning of an era of regenerative stem-cell treatment remains to be seen, but they clearly send a powerful signal to the field.

0
0
Loading